絞り込み

16403

広告

Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease.

著者 Kimachi M , Furukawa TA , Kimachi K , Goto Y , Fukuma S , Fukuhara S
Cochrane Database Syst Rev.2017 Nov 06 ; 11():CD011373.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (41view , 0users)

Full Text Sources

Miscellaneous

Chronic kidney disease (CKD) is an independent risk factor for atrial fibrillation (AF), which is more prevalent among CKD patients than the general population. AF causes stroke or systemic embolism, leading to increased mortality. The conventional antithrombotic prophylaxis agent warfarin is often prescribed for the prevention of stroke, but risk of bleeding necessitates regular therapeutic monitoring. Recently developed direct oral anticoagulants (DOAC) are expected to be useful as alternatives to warfarin.
PMID: 29105079 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード